CDT · CDT Equity Inc. · Financials
$0.55
-0.05 (-8.17%)
At close · Sep 10
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months from the date of the filing of this Quarterly Report. This is based on our analysis under applicable accounting principles. These unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.”View the 10-Q filed Aug 12, 2026
Market Cap
$484,982
Shares
786,670
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$39.22M
-120.3%
FY2025
Diluted EPS
-$11,778.90
+98.1%
FY2025
Operating Cash Flow
-$15.56M
-60.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $3.36M | $5.05M | $3.38M | $90K | $37K | |
| $31.49M | $31.7M | $12.04M | $5.17M | $3.05M | |
| $34.85M | $36.76M | $15.42M | $5.26M | $3.16M | |
| -$34.85M | -$36.76M | -$15.42M | -$5.26M | -$3.16M | |
| — | $200K | $32K | — | $100K | |
| — | — | — | $15K | $1.98M | |
| -$2.3M | -$2.47M | -$2.38M | $4.73M | -$1.73M | |
| — | — | — | — | -$129K | |
| — | -$39.22M | -$17.8M | -$536K | $773.5K | |
| — | — | — | — | $374.86K | |
| -$37.15M | -$39.22M | -$17.8M | -$535K | -$4.89M | |
| -$37.26M | -$39.65M | -$17.8M | -$799K | -$4.13M | |
| USD/shares | $35,799.60 | -$11,778.90 | -$615,986.20 | -$23,700.00 | -$390,000.00 |
| USD/shares | $35,799.60 | -$11,778.90 | -$615,986.20 | -$267,600.00 | -$390,000.00 |
| shares | — | 3330 | 28.9 | 22.3246 | 12.4826 |
| shares | — | 3330 | 28.9 | 22.6313 | 12.4826 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.96×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 54 similar-size Biotechnology companies (of 537 listed).